Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study. / Nørøxe, Dorte Schou; Østrup, Olga; Yde, Christina Westmose; Ahlborn, Lise Barlebo; Nielsen, Finn Cilius; Michaelsen, Signe Regner; Larsen, Vibeke Andrée; Skjøth-Rasmussen, Jane; Brennum, Jannick; Hamerlik, Petra; Poulsen, Hans Skovgaard; Lassen, Ulrik.
I: OncoTarget, Bind 10, Nr. 43, 2019, s. 4397-4406.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study
AU - Nørøxe, Dorte Schou
AU - Østrup, Olga
AU - Yde, Christina Westmose
AU - Ahlborn, Lise Barlebo
AU - Nielsen, Finn Cilius
AU - Michaelsen, Signe Regner
AU - Larsen, Vibeke Andrée
AU - Skjøth-Rasmussen, Jane
AU - Brennum, Jannick
AU - Hamerlik, Petra
AU - Poulsen, Hans Skovgaard
AU - Lassen, Ulrik
PY - 2019
Y1 - 2019
N2 - Background: Glioblastoma (GB) is an incurable brain cancer with limited treatment options. The aim was to test the feasibility of using cell-free DNA (cfDNA) to support evaluation of treatment response, pseudo-progression and whether progression could be found before clinical and/or radiologic progression. Results: CfDNA fluctuated during treatment with the highest levels before diagnostic surgery and at progression. An increase was seen in 3 out of 4 patients at the time of progression while no increase was seen in 3 out of 4 patients without progression. CfDNA levels could aid in 3 out of 3 questionable cases of pseudo-progression. Methods: Eight newly diagnosed GB patients were included. Blood samples were collected prior to diagnosis, before start and during oncologic treatment until progression. Seven patients received concurrent radiotherapy/Temozolomide with adjuvant Temozolomide with one of the patients included in a clinical trial with either immunotherapy or placebo as add-on. One patient received radiation alone. CfDNA concentration was determined for each blood sample. Conclusions: It was feasible to measure cfDNA concentration. Despite the limited cohort size, there was a good tendency between cfDNA and treatment course and -response, respectively with the highest levels at progression.
AB - Background: Glioblastoma (GB) is an incurable brain cancer with limited treatment options. The aim was to test the feasibility of using cell-free DNA (cfDNA) to support evaluation of treatment response, pseudo-progression and whether progression could be found before clinical and/or radiologic progression. Results: CfDNA fluctuated during treatment with the highest levels before diagnostic surgery and at progression. An increase was seen in 3 out of 4 patients at the time of progression while no increase was seen in 3 out of 4 patients without progression. CfDNA levels could aid in 3 out of 3 questionable cases of pseudo-progression. Methods: Eight newly diagnosed GB patients were included. Blood samples were collected prior to diagnosis, before start and during oncologic treatment until progression. Seven patients received concurrent radiotherapy/Temozolomide with adjuvant Temozolomide with one of the patients included in a clinical trial with either immunotherapy or placebo as add-on. One patient received radiation alone. CfDNA concentration was determined for each blood sample. Conclusions: It was feasible to measure cfDNA concentration. Despite the limited cohort size, there was a good tendency between cfDNA and treatment course and -response, respectively with the highest levels at progression.
U2 - 10.18632/oncotarget.27030
DO - 10.18632/oncotarget.27030
M3 - Journal article
C2 - 31320993
VL - 10
SP - 4397
EP - 4406
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 43
ER -
ID: 237193411